Pacific Biosciences Of California (PACB) Free Cash Flow Growth (5y) (2015 - 2026)
Pacific Biosciences Of California (PACB) Free Cash Flow Growth (5y) (2015 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 183.58 Bn | 176.28 Bn | 6.27 Bn |
| 2 | Stryker | 129.01 Bn | 126.13 Bn | 3.81 Bn |
| 3 | Medtronic | 108.52 Bn | 99.30 Bn | 6.41 Bn |
| 4 | Boston Scientific | 68.67 Bn | 67.22 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 48.33 Bn | 44.66 Bn | 1.29 Bn |
| 6 | Dexcom | 28.34 Bn | 27.23 Bn | 750.30 Mn |
| 7 | GE HealthCare Technologies | 28.07 Bn | 25.79 Bn | 1.98 Bn |
| 8 | Smith & Nephew | 26.89 Bn | 26.31 Bn | - |
| 9 | Koninklijke Philips | 24.12 Bn | 21.00 Bn | 2.07 Bn |
| 10 | Pacific Biosciences Of California | 415.91 Mn | 139.95 Mn | 12.84 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -15.22% |
| Dec 31, 2025 | -6.82% |
| Sep 30, 2025 | -0.30% |
| Jun 30, 2025 | -4.42% |
| Mar 31, 2025 | -21.10% |
| Dec 31, 2024 | -11.99% |
| Sep 30, 2024 | -19.82% |
| Jun 30, 2024 | -25.13% |
| Mar 31, 2024 | -24.53% |
| Dec 31, 2023 | -25.63% |
| Sep 30, 2023 | -35.84% |
| Jun 30, 2023 | -22.66% |
| Mar 31, 2023 | -38.78% |
| Dec 31, 2022 | -25.23% |
| Sep 30, 2022 | -26.09% |
| Jun 30, 2022 | -31.77% |
| Mar 31, 2022 | -33.71% |
| Dec 31, 2021 | -17.31% |
| Jun 30, 2021 | 4.44% |
| Mar 31, 2021 | -2.55% |